This quiz, the first in 4 part series, focuses on pivotal data from the INTEGUMENT trials in atopic dermatitis.
Atopic dermatitis affects approximately 10 to 20% of children and up to 10% of adults worldwide, with many experiencing moderate-to-severe disease with a significant impact on quality of life. Despite its prevalence, effective treatment options have historically been limited, particularly for patients who do not respond to topical corticosteroids or conventional systemic therapies. Until recently, therapeutic advancements have been slow, leaving many patients with persistent symptoms and few alternatives.
However, in 2024 alone, 4 therapies—roflumilast cream (Zoryve), lebrikizumab (Ebglyss), nemolizumab (Nemluvio), and tapinarof cream 1% (Vtama)—received approvals for atopic dermatitis in different populations, marking a significant expansion of available treatment options.
On July 09, 2024, the US Food and Drug Administration (FDA) approved the supplemental new drug application for roflumilast cream, 0.15%, for the treatment of mild to moderate atopic dermatitis in adult and pediatric patients 6 years of age and older. This approval was based on positive results from 3 phase 3 studies, as well as a Phase 2 dose-ranging study, and two Phase 1 pharmacokinetic studies. The phase 3 INTEGUMENT-1 and -2 studies each met their primary endpoint of IGA Success, defined as a validated Investigator Global Assessment – Atopic Dermatitis (vIGA-AD) score of Clear or Almost Clear plus a 2-grade improvement from baseline at week 4 (P <.001).
This quiz is 1 of 4 in a series designed to reinforce knowledge of the data supporting these new treatments. By engaging with these quizzes, clinicians can better understand how these therapies fit into clinical practice and improve patient outcomes.
Test your knowledge below on pooled data from INTEGUMENT-1 and INTEGUMENT-2 trials and stay up to date with the latest clinical advancements in atopic dermatitis treatment.
1. True or False: The INTEGUMENT trials represent the first large-scale, randomized Phase 3 studies evaluating a PDE4 inhibitor in mild to moderate atopic dermatitis.
References: